Navigation Links
BioDelivery Sciences to Host Business Update Webcast and Conference Call on Tuesday, November 15, 2011 at 8:30 AM Eastern Time
Date:11/14/2011

e E.U. (where it will be marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation for the treatment of opioid dependence.  Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron).  BDSI's headquarters is located in Raleigh, North Carolina.  For more information, visit www.bdsi.com.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL is registered trademark of Meda Pharma GmbH & Co. KG.

Cautionary Note on Forward-Looking Statements

This press release, the presentation described herein and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioDelivery Sciences Initiates Confirmatory Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
2. Samuel J. Sears, Jr. Appointed to BioDelivery Sciences Board of Directors
3. BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence
4. BioDelivery Sciences Announces Upcoming Presentations at Three Investor Conferences
5. BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada
6. BioDelivery Sciences to Present at the Jeffries Global Healthcare Conference
7. BioDelivery Sciences Provides Update on Status of Modified REMS Program for ONSOLIS
8. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
9. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
10. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
11. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  XBiotech announced today interim results from its ... US for its anti-cancer agent Xilonix™. ... being evaluated in advanced colorectal cancer patients where ... endpoint of the study is overall survival, comparing ... population provided only palliative therapy for cachexia. ...
(Date:9/2/2014)... CALGARY, Alberta , September 2, 2014 ... der "State of the Art and Featured Research Session" ... Resverlogix Corp. (TSX: RVX) gab heute bekannt, dass Dr. Jan ... beim Kongress des europäischen Kardiologenverbandes (ESC) 2014 in ... In seinem Vortrag mit dem Titel " Effects of ...
(Date:9/2/2014)... NEW YORK , Sept. 2, 2014 /PRNewswire/ ... report is available in its catalogue: ... 2014 http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... H2, 2014 Summary GlobalData,s clinical ... Review, H2, 2014" provides data on the Acute ...
Breaking Medicine Technology:XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 3RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 4RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 5RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
... medication with published data,demonstrating symptom control at 13 ... Oct. 29 Shire plc (LSE: SHP, Nasdaq:,SHPGY), ... a 13-hour analog classroom study in school-aged children ... Disorder (ADHD). In this,study, researchers found that VYVANSE ...
... Zealand and Canada Find Ruyan E-cigarettes Safe; ... Results Apply Only to Ruyan Products, ... publication of a report that tested the safety of its ... that users find satisfies their desire for tobacco. The,report summary ...
Cached Medicine Technology:Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 2Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 3Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 4Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 5Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 6Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 7Comprehensive Safety Tests Published on Ruyan(R) Smoking Alternatives 2Comprehensive Safety Tests Published on Ruyan(R) Smoking Alternatives 3
(Date:9/2/2014)... September 02, 2014 Anti-aging is ... and services such as anti-wrinkle treatments and products, ... treatments, and breast augmentation becoming much sought after ... U.S.-based market intelligence firm Transparency Market Research, the ... will grow to USD 191.7 billion by 2019, ...
(Date:9/2/2014)... 02, 2014 Evolve Medical Clinics, ... primary and urgent care arena, is having its ... with a health fair the clinic is sponsoring. ... to assist patients in achieving high quality, convenient ... pricing structure is a groundbreaking change in healthcare. ...
(Date:9/2/2014)... 2014 When weather conditions are right, tornadoes ... leaving behind a path of destruction. In fact, the United ... of 1,253 tornadoes per year. Rainbow International offers the following ... tornado strikes., , Select a safe place ... your home with no windows to stay during the storm. ...
(Date:9/2/2014)... Last year, SIGVARIS took graduated compression ... a luxurious line of graduated compression socks with natural fibers. ... Socks are joining the SIGVARIS MEDICAL collection for those who ... of natural cotton fibers. , “When people step into ... socks as soft as the finest cashmere,” says Clay Walker, ...
(Date:9/2/2014)... 2014 The first trial involving ... implant ( http://www.depuypinnacle-lawsuit.com/depuy-pinnacle-hip-implant/ ) will soon get underway, ... District Court, Northern District of Texas, Bernstein Liebhard ... Johnson and its DePuy Orthopaedics unit are facing ... caused recipients to suffer serious and debilitating complications. ...
Breaking Medicine News(10 mins):Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 3Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 3Health News:Act Quickly in Case of Tornado: Rainbow International® Offers Tips on How to Be Prepared for a Tornado 2Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 4
... emerged a heartening development.The World Health Organisation (WHO) has ... based Institute for OneWorld Health, a non-profit drug firm, ... ,Paromomycin IM Injection is a cost-effective treatment ... parasitic disease after malaria. ,It is ...
... A new study has found that single tablets containing ... to controlling increasing blood pressure in people with ... ACCOMPLISH (Avoiding Cardiovascular Events through Combination Therapy in Patients ... of researchers led by Ken Jamerson at the University ...
... on stem cells as a cure for infertility has made ... to grow mature sperm from adult stem cells, says Dr.Karim ... Dr. Nayernia, a professor of stem biology at the ... team had successfully coaxed the embryonic stem cells of mice ...
... Calcutta will reach out to more poor people with free ... the three healthcare units we have opened in Kolkata are ... target to reach out to more number of people by ... Gupta told a press conference Tuesday. ,"We have ...
... taken ill Wednesday after inhaling methane gas leaking from a colliery ... leak was reported early morning from the Bathdih colliery of Bharat ... ,The 10 people of Barari Basti area who fell ... to be in critical condition. ,BCCL officials have rushed ...
... girl dragged along by her headlocks, on the ground then, covering ... her head is smashed with a concrete block, blood oozes from ... heard. ,In the eyes of many in her ... was to love a boy from another religion. She was a ...
Cached Medicine News:Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 2Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 3Health News:Single-tablet With Two Drugs may Help Control High BP Better 2Health News:Stem Cell Answer to Infertility in Five Years, Says Scientist 2Health News:Women in Iraq More Unsafe Than Ever 2
Monitorr ICP external CSF drainage and monitoring system with patient line one way valve....
... and skull base surgery. Complete implant ... pediatric neurosurgery, bony defects of the ... regions, neuro trauma. Dedicated neuro/skull base ... one compact kit. MRI and CT ...
Ralk Hand Drill, with Jacobs chuck, wrench-locking, with axial channel for Kirschner wires, for twist drills up to 7 mm , for Kirschner wires up to 4 mm...
Hudson Cranial Drill, complete, consisting of: brace; with extension piece and 4 burs...
Medicine Products: